For two decades, computer system validation in pharma became a byword for documentation volume — thick binders of scripted tests, much of it disconnected from actual risk. The FDA's Computer Software Assurance (CSA) approach, and GAMP 5 Second Edition, exist to fix that: less paperwork, more assurance, effort focused where it protects product quality and data integrity. This article explains how to make the shift.
The problem CSA solves
Traditional CSV too often optimized for evidence of testing rather than confidence in the system. Teams scripted exhaustive tests for low-risk, vendor-standard functionality, while the documentation burden discouraged frequent, valuable changes. The result was paradoxical: large validation packages that added cost without proportionally adding assurance.
CSA reframes the question from "how much can we document?" to "what could go wrong, and how do we gain confidence it won't?"
Critical thinking first
CSA begins with critical thinking about intended use and risk:
- What is the system used for, and what is the impact on product quality, patient safety and data integrity if it fails?
- Which features are high-risk and warrant rigorous, scripted testing — and which are low-risk, vendor-standard functions where lighter approaches suffice?
- What assurance already exists — from the supplier's development and testing — that we can leverage rather than duplicate?
This risk-based triage is the heart of CSA. Effort is concentrated where failure matters.
A spectrum of testing, not one size
CSA explicitly endorses a range of assurance activities, matched to risk:
- Scripted testing for high-risk functionality, where detailed, pre-approved steps and evidence are justified.
- Unscripted / exploratory testing for lower-risk features, where a skilled tester verifies behavior without exhaustive scripting.
- Leveraged supplier activities, where a qualified vendor's testing and documentation reduce what you must repeat.
The corresponding records are also scaled — capturing what is needed for confidence and traceability, not documentation for its own sake.
Leverage the supplier — but qualify them
A central enabler of CSA is leveraging supplier assurance. That is only defensible if the supplier is properly assessed. A qualified vendor — with a credible quality system and transparent development and testing practices — lets you rely on their work and focus your validation on configuration and intended use. An unassessed vendor does not.
This is why vendor and system qualification is inseparable from a modern, risk-based CSV program.
Practical steps to adopt CSA
- Risk-tier your system inventory by impact on quality, safety and data integrity.
- Define assurance approaches per tier — scripted, unscripted or leveraged — and write it into your validation procedure.
- Qualify your key suppliers so leverage is justified and documented.
- Right-size records — capture evidence proportionate to risk, with clear traceability to requirements.
- Retrain the team — CSA depends on judgment; testers and reviewers need to understand the why, not just follow templates.
Data integrity is non-negotiable
CSA reduces low-value documentation; it does not relax data-integrity expectations. Audit trails, access control and ALCOA+ controls remain essential regardless of testing approach — and in a leaner validation model, the design of those controls deserves more attention, not less.
The payoff
Done well, CSA delivers more assurance for less effort: faster system deployment and change, validation focused on real risk, and teams that understand what they are protecting. It is not a shortcut — it is validation that finally matches effort to risk.
PharmExpert delivers risk-based CSV/CSA, vendor qualification and data-integrity controls aligned to GAMP 5 and FDA CSA. Explore our CSV & Digitalization services.